Lord, Abbett & Co
AUPH icon

Lord, Abbett & Co’s Aurinia Pharmaceuticals AUPH Stock Holding History

Lord, Abbett & Co’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-428,363
Closed -$5.92M – 637
2020
Q4 		$5.92M Sell
428,363
-22,805
-5% -$332K 0.02% 591
2020
Q3 		$6.65M Buy
451,168
+122,902
+37% +$1.78M 0.02% 534
2020
Q2 		$5.33M Buy
328,266
+6,808
+2% +$109K 0.02% 565
2020
Q1 		$4.67M Buy
+321,458
New +$5.67M 0.02% 545

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Lord, Abbett & Co's AUPH Position: Q1 2021 in Review

Lord, Abbett & Co sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2021, closing a stake of 428,363 shares — an estimated $5.92M sold.

Lord, Abbett & Co first reported a position in AUPH in Q1 2020 and held it in 4 quarters. The position peaked at $6.65M in Q3 2020. 170 funds tracked by Wall St. Rank hold AUPH as of Q1 2021.

  • Lord, Abbett & Co reported no remaining Aurinia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Lord, Abbett & Co sold 428,363 Aurinia Pharmaceuticals shares in Q1 2021, an estimated $5.92M.
  • Lord, Abbett & Co first reported a position in Aurinia Pharmaceuticals in Q1 2020 and held it in 4 quarters.
  • Lord, Abbett & Co's Aurinia Pharmaceuticals position peaked at $6.65M in Q3 2020.
  • 170 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2021.

Based on Lord, Abbett & Co's 13F filing for Q1 2021, filed 11 May 2021.